Zarutatug vedotin

维扎鲁妥塔单抗

Report date: 2026/04/16 20:00:17

First In Class

Base Information

Drug NameZarutatug vedotin

Drug Alias NameTORL-3-600

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker +[4]

Mechanisms of ActionTubulin polymerisation inhibitorsCadherin-17 inhibitors

TargetsTubulinCadherin-17

Therapy Area/IndicationsSolid tumoursColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesTorl Biotherapeutics LLC

China Registration ClassN/A

Develop Information

Active CompaniesTorl Biotherapeutics LLC

Inactive CompaniesN/A

Active IndicationsSolid tumoursColorectal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A